
Sign up to save your podcasts
Or


The U.S. government’s Covid-19 strategy has been to rely on developing vaccines and treatments, rather than emphase measures to limit the spread of the disease. That could delay the return to normal life for Americans. One report suggests that if the vaccine program has any hiccups, we could be living with the virus well into 2023. Health reporter Naomi Kresge reports on the cost of the government’s focus on developing drugs rather than changing behavior.
See omnystudio.com/listener for privacy information.
By Bloomberg3.7
805805 ratings
The U.S. government’s Covid-19 strategy has been to rely on developing vaccines and treatments, rather than emphase measures to limit the spread of the disease. That could delay the return to normal life for Americans. One report suggests that if the vaccine program has any hiccups, we could be living with the virus well into 2023. Health reporter Naomi Kresge reports on the cost of the government’s focus on developing drugs rather than changing behavior.
See omnystudio.com/listener for privacy information.

78,629 Listeners

32,185 Listeners

6,806 Listeners

29,042 Listeners

15,454 Listeners

2,691 Listeners

402 Listeners

2,179 Listeners

1,971 Listeners

427 Listeners

12,120 Listeners

17,797 Listeners

969 Listeners

112,700 Listeners

195 Listeners

30 Listeners

10,063 Listeners

4 Listeners

58 Listeners

233 Listeners

229 Listeners

64 Listeners

79 Listeners

82 Listeners

394 Listeners

19 Listeners

12 Listeners

7 Listeners

2 Listeners

72 Listeners

1,151 Listeners

186 Listeners